Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis

NCT00618540 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Histiocytosis, Langerhans-cell

Interventions

BIOLOGICAL: alemtuzumab
DRUG: fludarabine phosphate
DRUG: melphalan
PROCEDURE: stem cell transplantation

Sponsor

Masonic Cancer Center, University of Minnesota